Mutations of the PIK3CA gene, inducing hyperactivation of the alpha isoform (p110α) of PI3K, occur in 28% to 46% of patients with HR+/human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) (4, 5). This evidence concerns the gene ERBB2 and breast carcinoma.